Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac Adds High-Speed Clinical Trial Blistering Equipment at US HQ

Published: Tuesday, May 15, 2012
Last Updated: Tuesday, May 15, 2012
Bookmark and Share
Almac acquires PharmaWorks TF3 machine to fulfil customer's needs by increasing blistering capacity.

Almac has announced the acquisition of the new PharmaWorks TF3 high-speed / large-format blister equipment. The addition addresses a growing industry need for outsourced clinical trial services and follows another recent acquisition, the Bosch GKF 702 over-encapsulation machine.

Both pieces of equipment will be housed in Almac’s North American headquarters in Souderton, PA, reinforcing the company’s global capacity by complementing existing equipment currently in the Craigavon, Northern Ireland global headquarters.

The cGMP-compliant equipment provides added value in Almac’s clinical manufacturing capabilities, strengthening the company’s focus on providing clients with a variety of high quality packaging solutions.

In a broader scope, it lends itself to strengthen Almac’s service portfolio that addresses the clinical packaging, labelling, and distribution needs of global clients.

Features of the TF3 include a 220mm x 290mm form area, colour vision system, automated seal registration, and a programmable punch station.

The machine is equipped with an automated feeder that can accommodate the input of up to 4 different products (tablets or capsules) simultaneously.

Capable of speeds averaging 50 indexes per minute, this machine provides convenient and efficient tool-less changeovers.

Almac evaluated a number of high-quality vendors when looking into the purchase of the new blistering equipment.

The TF3 was chosen based on its flexible and versatile nature and its ability to most suitably fulfil Almac’s need to expand to meet the growing needs of global clients.

“The purchase of the PharmaWorks TF3 machine will allow Almac to fulfil our customer's needs by increasing our blistering capacity,” said Dan Megill, Director of Operations at Almac.

Megill continued, “This machine offers leading functionality and supplies Almac with a highly flexible format to support our various clients and their packaging needs.

PharmaWorks are at the forefront of forming technology and the support we have received from them has been tremendous. We are pleased with this acquisition and expect it to contribute greatly to Almac’s overall productivity while enhancing our core services.”

Ben Brower, PharmaWorks VP, also commented “As our tag line on the TF3 brochure states - “No compromise: efficiency and flexibility across the entire spectrum of blisters”.

I cannot think of a better summary of the TF3. We have included features and technology to solve many of the pharmaceutical industry’s blister production challenges. From our user friendly interface to our laser seal and punch registration features we feel the machine is state-of-the-art.

We are proud to count Almac as a continued customer and partner in providing the highest quality in pharmaceutical blister production.

Almac will be able to offer its customers unparalleled and equal efficiency whether producing HUD type blisters or large BINGO type blisters.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Launches US Serialisation Solution
Company has announced an expansion to its serialisation capabilities to include its US commercial packaging facility in partnership with Optel Vision.
Thursday, May 12, 2016
Almac Addresses Industry Demand for Multiparticulate Drug Products
Company is providing scalable fluid bed and encapsulation technologies to its global partners.
Friday, October 09, 2015
Almac Group Expands Asia Pacific Presence
Company opens new regional headquarters and clinical trial supply facility in Singapore.
Thursday, July 16, 2015
Novozymes Biopharma Announces Collaboration with Almac
Combined service offers drug development companies efficiencies in time and resource.
Tuesday, October 22, 2013
Almac Expands US & UK Commercial Facilities
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic.
Tuesday, October 22, 2013
Almac Announces Further Expansion and 229 New Jobs
Dual expansion with completion of a new non-GMP drug development facility.
Monday, June 17, 2013
Almac Launches US Commercial Packaging Operations in Audubon
Company also announces launch of new client partnership.
Monday, May 20, 2013
Almac Receives FDA Inspection Approval
Successful inspection of analytical facilities at Almac’s Craigavon Headquarters, Northern Ireland from the US FDA.
Thursday, February 21, 2013
Almac Doubles Drug Product Development Capacity with a New Non-GMP Facility
New facility offers clients greater flexibility and speed in formulation and process development.
Tuesday, January 15, 2013
Charlie Morris Appointed to Almac’s Clinical Technologies Executive Team
Mr. Morris joins Almac as Vice President of new products and services.
Thursday, December 13, 2012
Almac Concludes Commercial API Manufacturing Facility Expansion Plans
Almac’s expansion is near completion and will be operational by the end of the year.
Tuesday, October 09, 2012
Almac Expands UK Commercial Capacity
Acquisition of new Noack N 623 blister packaging line from Romaco.
Friday, October 05, 2012
Almac Installs Uhlmann Blister Line in New US Commercial Packaging Facility
Acquisition of a high-speed blister line in Audubon, PA.
Monday, July 02, 2012
Almac Introduces QP Facilitation Programme for Conducting Trials in the European Union
Programme vastly simplifies and expedites the QP release process.
Thursday, June 14, 2012
Almac Strengthens Board with Appointment of New Financial Director
Kevin Stephens’ promotion to FD is set to further enhance the Group’s financial performance and programme for international growth.
Tuesday, April 10, 2012
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!